Q32 Bio Inc.
QTTB
$1.60
-$0.025-1.54%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 68.79% | 26.45% | 92.23% | 67.28% | -98.02% |
| Gross Profit | -68.79% | 54.15% | -156.00% | -178.70% | 96.84% |
| SG&A Expenses | 2.04% | 41.77% | 103.65% | 83.03% | 107.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.84% | 30.31% | 94.82% | 70.98% | 43.83% |
| Operating Income | 23.84% | 43.72% | -141.27% | -146.31% | -101.32% |
| Income Before Tax | -1,172.01% | 41.10% | -25.98% | -167.42% | 115.05% |
| Income Tax Expenses | -- | -733.99% | -- | -- | -- |
| Earnings from Continuing Operations | -1,172.01% | 47.58% | -25.40% | -192.37% | 115.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,172.01% | 47.58% | -25.40% | -192.37% | 115.05% |
| EBIT | 23.84% | 43.72% | -141.27% | -146.31% | -101.32% |
| EBITDA | 24.01% | 43.91% | -143.56% | -148.89% | -103.15% |
| EPS Basic | -187.47% | 98.47% | 96.40% | 91.50% | 105.21% |
| Normalized Basic EPS | -179.36% | 95.53% | 96.53% | 92.22% | 105.21% |
| EPS Diluted | 85.71% | 98.47% | 96.40% | 91.49% | 68.11% |
| Normalized Diluted EPS | -286.13% | 95.53% | 96.53% | 92.22% | 102.22% |
| Average Basic Shares Outstanding | 1,125.52% | 3,336.99% | 3,387.27% | 3,338.98% | 188.83% |
| Average Diluted Shares Outstanding | 422.56% | 3,336.99% | 3,387.27% | 3,338.98% | 577.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |